The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?

References

• Sarhadi VK, Armengol G. Molecular Biomarkers in cancer. Biomolecules. 2022;12(8):1021. doi: 10.3390/biom12081021
   PubMed Web of Science ®Google Scholar
• Malone ER, Oliva M, Sabatini PJB, et al. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1). doi: 10.1186/s13073-019-0703-1
   PubMed Web of Science ®Google Scholar
• Offin M, Liu D, Drilon A. Tumor-agnostic drug development. Am Soc Clin Oncol Educ B. 2018;(38):184–187. doi: 10.1200/edbk_200831
   PubMedGoogle Scholar
• Incorvaia L, Russo A, Cinieri S. The molecular tumor board: a tool for the governance of precision oncology in the real world. Tumori. 2022;108(4):288–290. doi: 10.1177/03008916211062266
   PubMed Web of Science ®Google Scholar
• Li K, Luo H, Huang L, et al. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020;20(1). doi: 10.1186/s12935-019-1091-8
   Web of Science ®Google Scholar
• Pećina-Šlaus N, Kafka A, Salamon I, et al. Mismatch repair pathway, genome stability and cancer. Front Mol Biosci. 2020;7: doi: 10.3389/fmolb.2020.00122
   PubMed Web of Science ®Google Scholar
• Motta R, Cabezas-Camarero S, Torres-Mattos C, et al. Immunotherapy in microsatellite instability metastatic colorectal cancer: current status and future perspectives. J Clin Trans Res. 2021;7(4):511.
   Google Scholar
• Malapelle U, Parente P, Pepe F, et al. Evaluation of micro satellite instability and mismatch repair status in different solid tumors: a multicenter analysis in a real world setting. Cells. 2021;10(8):1878. doi: 10.3390/cells10081878
   PubMed Web of Science ®Google Scholar
• Zheng K, Wan H, Zhang J, et al. A novel NGS-based microsatellite instability (MSI) status classifier with 9 loci for colorectal cancer patients. J Transl Med. 2020;18(1). doi: 10.1186/s12967-020-02373-1
   Web of Science ®Google Scholar
• Lorenzi M, Amonkar M, Zhang J, et al. Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review. J Oncol. 2020;2020:1–17. doi: 10.1155/2020/1807929
   Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi: 10.1056/nejmoa1500596
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;80. doi: 10.1126/science.aan6733
   Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi: 10.1016/S1470-2045(17)30422-9
   PubMed Web of Science ®Google Scholar
• Sholl LM, Hirsch FR, Hwang D, et al. Tumor mutation burden: promises and challenges a perspective from the IASLC pathology committee. J Thorac Oncol. 2020;15(9):1409–1424. doi: 10.1016/j.jtho.2020.05.019
   PubMed Web of Science ®Google Scholar
• Galvano A, Gristina V, Malapelle U, et al. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. ESMO Open. 2021;6(3):100124. doi: 10.1016/j.esmoop.2021.100124
   PubMed Web of Science ®Google Scholar
• Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021;27(17):4685–4689. doi: 10.1158/1078-0432.CCR-21-0327
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. doi: 10.1016/S1470-2045(20)30445-9
   PubMed Web of Science ®Google Scholar
• Kang YJ, O’Haire S, Franchini F, et al. A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours. Sci Rep. 2022;12(1). doi: 10.1038/s41598-022-23319-1
   Web of Science ®Google Scholar
• Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–747. doi: 10.1038/s41571-018-0113-0
   PubMed Web of Science ®Google Scholar
• Hechtman JF. NTRK insights: best practices for pathologists. Mod Pathol. 2022;35(3):298–305. doi: 10.1038/s41379-021-00913-8
   PubMed Web of Science ®Google Scholar
• Siozopoulou V, Smits E, De Winne K, et al. NTRK fusions in sarcomas: diagnostic challenges and clinical aspects. Diagnostics. 2021;11(3):478. doi: 10.3390/diagnostics11030478
   Web of Science ®Google Scholar
• Russo A, Incorvaia L, Malapelle U, et al. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian scientific societies. Crit Rev Oncol Hematol. 2021;165:103436. doi: 10.1016/j.critrevonc.2021.103436
   PubMed Web of Science ®Google Scholar
• Han SY. Trk inhibitors: tissue-agnostic anti-cancer drugs. Pharmaceuticals. 2021;14(7):632. doi: 10.3390/ph14070632
   Web of Science ®Google Scholar
• Zaman A, Wu W, Bivona TG. Targeting oncogenic braf: past, present, and future. Cancers. 2019;11(8):1197. doi: 10.3390/cancers11081197
   PubMed Web of Science ®Google Scholar
• Vanni I, Tanda ET, Spagnolo F, et al. The current state of molecular testing in the BRAF-Mutated melanoma landscape. Front Mol Biosci. 2020;7. doi: 10.3389/fmolb.2020.00113
   Web of Science ®Google Scholar
• Owsley J, Stein MK, Porter J, et al. Prevalence of class I–III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med. 2021;246(1):31–39. doi: 10.1177/1535370220959657
   Web of Science ®Google Scholar
• Sholl LM. A narrative review of BRAF alterations in human tumors: diagnostic and predictive implications. Precis Cancer Med. 2020;3:26–26. doi: 10.21037/pcm-2019-ppbt-02
   Google Scholar
• Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–1243. doi: 10.1016/S1470-2045(20)30321-1
   PubMed Web of Science ®Google Scholar
• Adashek JJ, Desai AP, Andreev-Drakhlin AY, et al. Hallmarks of RET and co-occurring genomic alterations in RET-aberrant cancers. Mol Cancer Ther. 2021;20(10):1769–1776. doi: 10.1158/1535-7163.MCT-21-0329
   PubMed Web of Science ®Google Scholar
• Santoro M, Moccia M, Federico G, et al. Ret gene fusions in malignancies of the thyroid and other tissues. Genes. 2020;11(4):424. doi: 10.3390/genes11040424
   PubMed Web of Science ®Google Scholar
• Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. The Lancet Oncology. 2022;23(10):1261–1273. doi: 10.1016/S1470-2045(22)00541-1
   PubMed Web of Science ®Google Scholar
• Iliakis G, Mladenov E, Mladenova V. Necessities in the processing of DNA double strand breaks and their effects on genomic instability and cancer. Cancers. 2019;11(11):1671. doi: 10.3390/cancers11111671
   PubMed Web of Science ®Google Scholar
• Russo A, Incorvaia L, Capoluongo E, et al. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian scientific societies. ESMO Open. 2022;7(3):100459. doi: 10.1016/j.esmoop.2022.100459
   PubMed Web of Science ®Google Scholar
• Passiglia F, Rizzo S, Rolfo C, et al. Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- Mutation testing in NSCLC patients: a pooled analysis. Curr Cancer Drug Targets. 2018;18(7):697–705. doi: 10.2174/1568009618666180308125110
   PubMed Web of Science ®Google Scholar
• Toh MR, Ngeow J. Homologous recombination deficiency: cancer predispositions and treatment implications. Oncology. 2021;26(9):e1526–e1537. doi: 10.1002/onco.13829
   Google Scholar
• Shao C, Wan J, Lam FC, et al. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies. Environ Mol Mutagen. 2022;63(6):308–316. doi: 10.1002/em.22505
   PubMed Web of Science ®Google Scholar
• Galvano A, Castiglia M, Rizzo S, et al. Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: a systematic review with meta-analysis. Cancers. 2020;12(3):534. doi: 10.3390/cancers12030534
   PubMed Web of Science ®Google Scholar
• Helleday T. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. Annals Of Oncology. 2016;27(5):755–757. doi: 10.1093/annonc/mdw048
   PubMed Web of Science ®Google Scholar
• Wang S, Ding Z. Fibroblast growth factor receptors in breast cancer. Tumor Biol. 2017;39(5):101042831769837. doi: 10.1177/1010428317698370
   Google Scholar
• Pant S, Schuler MH, Iyer G, et al. Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: expansion cohort results. J Clin Oncol. 2023;41(4_suppl):610–610. doi: 10.1200/jco.2023.41.4_suppl.610
   Google Scholar
• Cabel L, Fuerea A, Lacroix L, et al. Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget. 2018;9(11):9741–9750. doi: 10.18632/oncotarget.24188
   PubMedGoogle Scholar
• Hierro C, Matos I, Martin-Liberal J, et al. Agnostic-histology approval of new drugs in oncology: are we already there? Clin Cancer Res. 2019;25(11):3210–3219. doi: 10.1158/1078-0432.CCR-18-3694
   PubMed Web of Science ®Google Scholar
• Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34(1):157–164. doi: 10.1007/s10555-015-9552-6
   PubMed Web of Science ®Google Scholar
• Grinda T, Rassy E, Pistilli B. Antibody–drug conjugate revolution in breast cancer: the road ahead. Curr Treat Options Oncol. 2023;24(5):442–465. doi: 10.1007/s11864-023-01072-5
   PubMed Web of Science ®Google Scholar
• Lim KHT, Kong HL, Chang KTE, et al. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: consensus of a Singapore task force. Asia Pac J Clin Oncol. 2022;18(4):394–403. doi: 10.1111/ajco.13727
   PubMed Web of Science ®Google Scholar
• Hechtman JF, Benayed R, Hyman DM, et al. Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547–1551. doi: 10.1097/PAS.0000000000000911
   PubMed Web of Science ®Google Scholar
• Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417–1427. doi: 10.1093/annonc/mdz204
   PubMed Web of Science ®Google Scholar
• Drilon A, Li G, Dogan S, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016;27(5):920–926. doi: 10.1093/annonc/mdw042
   PubMed Web of Science ®Google Scholar
• Church AJ, Calicchio ML, Nardi V, et al. Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018;31(3):463–473. doi: 10.1038/modpathol.2017.127
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol. 2019;72(7):460–467. doi: 10.1136/jclinpath-2018-205679
   PubMed Web of Science ®Google Scholar
• Gian LD, Lorena B, Cinzia A, et al. Microsatellite instability in colorectal cancer. Acta Biomed. 2018;89(Suppl 9):97. doi: 10.23750/abm.v89i9-S.7960
   PubMedGoogle Scholar
• Rosen DG, Cai KQ, Luthra R, et al. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol. 2006;19(11):1414–1420. doi: 10.1038/modpathol.3800672
   PubMed Web of Science ®Google Scholar
• Malapelle U, Parente P, Pepe F, et al. Impact of pre-analytical factors on MSI test accuracy in mucinous colorectal adenocarcinoma: a multi-assay concordance study. Cells. 2020;9(9):2019. doi: 10.3390/cells9092019
   PubMed Web of Science ®Google Scholar
• Hechtman JF, Rana S, Middha S, et al. Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Mod Pathol. 2020;33(5):871–879. doi: 10.1038/s41379-019-0414-6
   PubMed Web of Science ®Google Scholar
• Coleman N, Hong L, Zhang J, et al. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open. 2021;6(6):100319. doi: 10.1016/j.esmoop.2021.100319
   PubMed Web of Science ®Google Scholar
• Pisapia P, Pepe F, Gristina V, et al. A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic. Mediastinum. 2021;5:27–27. doi: 10.21037/MED-21-9
   PubMedGoogle Scholar
• Iannantuono GM, Riondino S, Sganga S, et al. NTRK gene fusions in solid tumors and TRK inhibitors: a systematic review of case reports and case series. J Pers Med. 2022;12(11):1819. doi: 10.3390/jpm12111819
   PubMed Web of Science ®Google Scholar
• Garcia‐Foncillas J, Bokemeyer C, Italiano A, et al. Indirect treatment comparison of larotrectinib versus entrectinib in treating patients with TRK gene fusion cancers. Cancers (Basel). 2022;14(7):1793. doi: 10.3390/cancers14071793
   PubMed Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–282. doi: 10.1016/S1470-2045(19)30691-6
   PubMed Web of Science ®Google Scholar
• Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777. doi: 10.1136/jitc-2021-003777
   PubMed Web of Science ®Google Scholar
• Gouda MA, Subbiah V. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open. 2023;8(2):100788. doi: 10.1016/j.esmoop.2023.100788
   PubMed Web of Science ®Google Scholar
• Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion–positive non–small-Cell lung cancer. N Engl J Med. 2020;383(9):813–824. doi: 10.1056/nejmoa2005653
   PubMed Web of Science ®Google Scholar
• Dickson D, Johnson J, Bergan R, et al. The master observational trial: a new class of master protocol to advance precision medicine. Cell. 2020;180(1):9–14. doi: 10.1016/j.cell.2019.12.009
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Fountzilas E, Nikanjam M, et al. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019. doi: 10.1016/j.ctrv.2020.102019
   PubMed Web of Science ®Google Scholar
• Subbiah V. The next generation of evidence-based medicine. Nat Med. 2023;29(1):49–58. doi: 10.1038/s41591-022-02160-z
   PubMed Web of Science ®Google Scholar
• Jørgensen JT. Site-agnostic biomarker-guided oncology drug development. Expert Rev Mol Diagn. 2020;20(6):583–592. doi: 10.1080/14737159.2020.1702521
   PubMed Web of Science ®Google Scholar
• Dittrich C. Basket trials: from tumour gnostic to tumour agnostic drug development. Cancer Treat Rev. 2020;90:102082. doi: 10.1016/j.ctrv.2020.102082
   PubMed Web of Science ®Google Scholar
• Skvortsova K, Stirzaker C, Taberlay P, et al. The DNA methylation landscape in cancer. Essays Biochem. 2019;63(6):797–811. doi: 10.1042/EBC20190037
   PubMed Web of Science ®Google Scholar
• Bhamidipati D, Subbiah V. Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies. Trends Cancer. 2023;9(3):237–249. doi: 10.1016/j.trecan.2022.11.003
   PubMed Web of Science ®Google Scholar
• Russo A, Incorvaia L, Del Re M, et al. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian scientific societies. ESMO Open. 2021;6(3):100164. doi: 10.1016/j.esmoop.2021.100164
   PubMed Web of Science ®Google Scholar
• Pisapia P, Pepe F, Sgariglia R, et al. Next generation sequencing in cytology. Cytopathology. 2021;32(5):588–595. doi: 10.1111/cyt.12974
   PubMed Web of Science ®Google Scholar
• Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032–4038. doi: 10.1200/JCO.2015.63.2497
   PubMed Web of Science ®Google Scholar
• Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell. 2017;171(7):1678–1691.e13. doi: 10.1016/j.cell.2017.11.009
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22(18):4585–4593. doi: 10.1158/1078-0432.CCR-15-3101
   PubMed Web of Science ®Google Scholar
• Li S, Hu R, Small C, et al. cfSNV: a software tool for the sensitive detection of somatic mutations from cell-free DNA. Nat Protoc. 2023;18(5):1563–1583. doi: 10.1038/s41596-023-00807-w
   PubMed Web of Science ®Google Scholar
• Krop IE, Jegede O, Grilley-Olson JE, et al. Results from molecular analysis for therapy choice (MATCH) arm I: taselisib for PIK3CA-mutated tumors. J Clin Oncol. 2018;36(15_suppl):101–101. doi: 10.1200/jco.2018.36.15_suppl.101
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Delord J-P, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–1334. doi: 10.1016/S1470-2045(15)00188-6
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120(8):2858–2866. doi: 10.1172/JCI37539
   PubMed Web of Science ®Google Scholar
• Nacchio M, Sgariglia R, Gristina V, et al. KRAS mutations testing in non-small cell lung cancer: the role of liquid biopsy in the basal setting. J Thoracic Dis. 2020;12(7):3836–3843. doi: 10.21037/jtd.2020.01.19
   PubMed Web of Science ®Google Scholar
• Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion–positive solid tumors. Cancer Discov. 2017;7(9):963–972. doi: 10.1158/2159-8290.CD-17-0507
   PubMed Web of Science ®Google Scholar